Trial · NCT03400800
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage Change in LDL-C From Baseline to Day 510 | Inclisiran | -49.3 | 95% Confidence Interval -51.22 to -47.48 | Percent change | |
| Percentage Change in LDL-C From Baseline to Day 510 | Placebo | 4.2 | 95% Confidence Interval 1.62 to 6.69 | Percent change | |
| Time-adjusted Percent Change in LDL-C Levels From Baseline After Day 90 and up to Day 540 | Inclisiran | -45.82 | 95% Confidence Interval -47.52 to -44.13 | Percent change | |
| Time-adjusted Percent Change in LDL-C Levels From Baseline After Day 90 and up to Day 540 | Placebo | 3.35 | 95% Confidence Interval 1.65 to 5.05 | Percent change | |
| Absolute Change In LDL-C From Baseline To Day 510 | Inclisiran | -50.91 | 95% Confidence Interval -53.14 to -48.67 | mg/dL | |
| Absolute Change In LDL-C From Baseline To Day 510 | Placebo | 0.96 | 95% Confidence Interval -1.26 to 3.18 | mg/dL | |
| Time-adjusted Absolute Change in LDL-C From Baseline After Day 90 and up to Day 540 | Inclisiran | -48.63 | 95% Confidence Interval -50.37 to -46.89 | mg/dL | |
| Time-adjusted Absolute Change in LDL-C From Baseline After Day 90 and up to Day 540 | Placebo | 0.31 | 95% Confidence Interval -1.42 to 2.04 | mg/dL | |
| Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Day 510 | Inclisiran | -63.64 | 95% Confidence Interval -65.55 to -61.74 | Percent change | |
| Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Day 510 | Placebo | 15.62 | 95% Confidence Interval 13.72 to 17.53 | Percent change | |
| Percentage Change in Total Cholesterol From Baseline to Day 510 | Inclisiran | -28.00 | 95% Confidence Interval -29.40 to -26.60 | Percent change | |
| Percentage Change in Total Cholesterol From Baseline to Day 510 | Placebo | 1.79 | 95% Confidence Interval 0.38 to 3.21 | Percent change | |
| Percentage Change in Apolipoprotein B (ApoB) From Baseline to Day 510 | Inclisiran | -38.15 | 95% Confidence Interval -39.76 to -36.54 | Percent change | |
| Percentage Change in Apolipoprotein B (ApoB) From Baseline to Day 510 | Placebo | 0.79 | 95% Confidence Interval -0.82 to 2.41 | Percent change | |
| Percentage Change in Non-HDL-C From Baseline to Day 510 | Inclisiran | -41.16 | 95% Confidence Interval -43.09 to -39.24 | Percent change | |
| Percentage Change in Non-HDL-C From Baseline to Day 510 | Placebo | 2.15 | 95% Confidence Interval 0.22 to 4.09 | Percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03400800/results